AngioDynamics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Joseph M. DeVivo, Chief Executive Officer, President and Director.

AngioDynamics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended Feb. 28, 2013. For the quarter, the company reported net sales were $81,571,000 against $51,567,000 a year ago. Operating income was $58,000 against loss of $2,757,000 a year ago. Loss before income taxes was $1,821,000 against $2,880,000 a year ago. Net loss was $992,000 against $1,768,000 a year ago. Diluted loss per share was $0.03 against $0.07 per share a year ago. Adjusted net income was $2,797,000 against $1,188,000 a year ago. Adjusted diluted earnings per share was $0.08 against $0.05 per share a year ago. EBITDA was $6,498,000 against $431,000 a year ago. Adjusted EBITDA was $12,723,000 against $6,094,000 a year ago. EBITDA per common share (assumes diluted) was $0.19 against $0.02 a year ago. Adjusted EBITDA per common share (assumes diluted) was $0.37 against $0.24 a year ago. Adjusted operating income was $6,283,000 against $2,906,000 a year ago. Net cash provided by operating activities was $10,000,000 against $6,789,000 a year ago. Additions to property, plant and equipment was $2,921,000 against $821,000 a year ago. The company generated $10,000,000 of operating cash flow in the third quarter, driven by strong operational financial discipline. This compared with $6,800,000 of cash flow last year. For the nine months, the company reported net sales were $251,994,000 against $251,994,000 a year ago. Operating income was $5,864,000 against $3,886,000 a year ago. Income before income taxes was $157,000 against $2,792,000 a year ago. Net income was $256,000 against $1,934,000 a year ago. Diluted earnings per share was $0.01 against $0.08 per share a year ago. Adjusted net income was $9,920,000 against $4,726,000 a year ago. Adjusted diluted earnings per share were $0.28 against $0.19 per share a year ago. EBITDA was $24,244,000 against $13,848,000 a year ago. Adjusted EBITDA was $39,709,000 against $19,410,000 a year ago. EBITDA per common share (assumes diluted) was $0.69 against $0.55 a year ago. Adjusted EBITDA per common share (assumes diluted) was $1.12 against $0.77 a year ago. Adjusted operating income was $21,329,000 against $9,448,000 a year ago. Net cash provided by operating activities was $15,514,000 against $12,502,000 a year ago. Additions to property, plant and equipment was $7,708,000 against $1,879,000 a year ago. The company provided earnings guidance for the fourth quarter and full year of 2013. For the quarter, the company expects revenue to be in a range of $85 million to $89 million in the quarter or a potential decline of 3% to 8% compared with last year's fiscal fourth quarter. The company expects adjusted EPS of $0.04 to $0.07. The company is anticipating sequential improvement from third quarter, but it do not expect the accrued compensation benefit to repeat, and gross margins are being dampened by absorbing some negative variances from volume reduction in its second half item. The company is also guiding to a wider range in user because of potential mix implications and its impact on its gross margins. The company expects EBITDA and cash to continue to demonstrate improvement as it carefully manage the business. For fiscal 2013, the company expects sales of $337 million to $341 million, EBITDA of $50 million to $52 million and adjusted EPS of $0.32 to $0.35. The company has lowered its full year expectations from 4% growth to 2% lower net sales at the midpoint for the year.

AngioDynamics Inc. announced that they will report Q3, 2013 results at 5:00 PM, Eastern Standard Time on Apr 08, 2013